Bramlett's team works
on liquid biopsy technologies for both DNA and RNA in human blood.
We're also making progress
on our liquid biopsy program since our last update, including the recently announced collaboration with Memorial Sloan Kettering Cancer Center, which is focused on furthering the basic understanding of the biology of circulating tumor DNA, or ctDNA, in different cancer types.
Besides planning their data analysis, researchers working
on liquid biopsies need to think carefully about their controls.
Not exact matches
Freenome, a
liquid biopsy startup that's looking to enter clinical trials, is working
on technology that would be able to detect cancer in the body, including its location and type, using only blood samples.
A glut of
liquid biopsy companies have emerged from universities and elsewhere in recent years to catch cancer by relying
on a patient's DNA, rather than having to extract their tissue.
TruePrime LB addresses current
liquid biopsy sensitivity and specificity issues by using adapted amplification of cancer - specific, large - fragment, cell - free DNA based
on primer - free technology that combines the enzymes TthPrimPol and Phi29 DNA polymerase.
He explains that DNA - based
liquid biopsies typically use standard blood collection tubes, and those based
on polymerase chain reaction (PCR) are particularly easy for clinical laboratorians to understand and implement.
Bramlett explains that manufacturers initially focused
on providing large panels of control samples to cover as many types of
liquid biopsy experiments as possible.
The third and newest approach to
liquid biopsies, exosome screening, relies
on circulating subcellular vesicles.
Larger biomarker signatures can be detected with technology from CDI Laboratories, which offers microarrays of functional human proteins (over 20,000
on a single array) to test the antibodies present in human
liquid biopsy samples, such as blood, serum, plasma, CSF, or tissue lysates.
And this past May Guardant Health announced it had raised $ 360 million from investors,
on top of earlier funding, with the goal of deploying its
liquid biopsy test to one million people over the next five years.
Bio-Rad will also host an Exhibitor Spotlight Presentation in Theater A, McCormick Place South, entitled: «Droplet Digital PCR and the Power of Partitioning: Advanced Applications for
Liquid Biopsy»
on Tuesday, April 17, at 12:30 PM.
Explore our diverse program focusing
on the major areas of clinical molecular oncology, including CRISPR, big data,
liquid biopsies, and more.
He recently shared his views with us
on clinical sequencing and
liquid biopsies.
Winners of best award presentations from the event included: Best Avian / Exotics Presentation Dr. Mary Thurber - «Detection of Avian Boravirus in Captive Thick - billed Parrots (Rhynchopsitta Pachyrhyncha) by RT - PCR and ELISA» Best Large Animal Presentation Dr. Lisa Gamsjaeger - «Sodium Iodide as a Preventative Strategy for Respiratory Disease in Preweaned Dairy Calves» Best Small Animal Presentation # 1 Dr. Catherine Belanger - «High - Pressure Balloon Valvuloplasty for Severe Pulmonic Stenosis: A Prospective Observational Study in 25 Dogs» Best Small Animal Presentation # 2 Dr. Chai - Fei Li - «Exosome - Associated Integrins as
Liquid Biopsy Biomarkers for Canine Glioma» Chris Smith Award Dr. Fauna Smith - «Eosinophilic Peritonitis in 8 Horses (1995 - 2015)» Gerald Ling Award Dr. Kate Farrell - «Evaluation of Pulse Oximetry as a Surrogate for Pao2 in Awake Dogs Breathing Room Air and Anesthetized Dogs
on Mechanical Ventilation» UC Davis, with the largest resident training program of any veterinary hospital in the country, is able to offer unique research and publishing opportunities not available elsewhere to veterinarians pursuing advanced training at teaching hospitals.
So far this year, American Veterinarian ® has reported
on immunotherapies that may slow growth or even shrink gliomas in dogs and humans, a
liquid biopsy assessment tool to detect tumor cell mutation, and a shared study between the American Kennel Club Canine Health Foundation and the V Foundation for Cancer Research
on the treatment of bladder cancer.